BFRI
Biofrontera Inc
NASDAQ: BFRI · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$1.08
-1.82% today
Updated 2026-04-30
Market cap
$12.58M
P/E ratio
—
P/S ratio
0.30x
EPS (TTM)
$-1.04
Dividend yield
—
52W range
$1 – $1
Volume
0.1M
Biofrontera Inc (BFRI) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $26.18M | $18.85M | $24.10M | $28.67M | $34.07M | $37.30M | $41.70M |
| Revenue growth (YoY) | — | -28.0% | +27.9% | +19.0% | +18.8% | +9.5% | +11.8% |
| Cost of revenue | $12.41M | $9.07M | $12.74M | $15.19M | $17.44M | $18.61M | $10.11M |
| Gross profit | $13.77M | $9.78M | $11.36M | $13.49M | $16.63M | $18.70M | $31.59M |
| Gross margin | 52.6% | 51.9% | 47.1% | 47.0% | 48.8% | 50.1% | 75.8% |
| R&D | — | — | — | $0.00 | $77000.00 | $2.09M | $3.72M |
| SG&A | $28.70M | $18.12M | $37.21M | $35.87M | $37.70M | $33.84M | $38.37M |
| Operating income | $-14.92M | $-9.61M | $-25.20M | $-18.58M | $-22.68M | $-17.21M | $-11.35M |
| Operating margin | -57.0% | -51.0% | -104.6% | -64.8% | -66.6% | -46.1% | -27.2% |
| EBITDA | $-8.15M | $-7.46M | $-36.76M | $934000.00 | $-18.45M | $-14.44M | $-10.48M |
| EBITDA margin | -31.1% | -39.6% | -152.5% | 3.3% | -54.2% | -38.7% | -25.1% |
| EBIT | $-8.81M | $-8.03M | $-37.30M | $-238000.00 | $-19.52M | $-15.59M | $-11.35M |
| Interest expense | $2.16M | $2.90M | $360000.00 | $370000.00 | $600000.00 | $2.11M | $452000.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-10.98M | $-10.99M | $-37.71M | $-640000.00 | $-20.13M | $-17.76M | $-10.54M |
| Net income growth (YoY) | — | -0.0% | -243.3% | +98.3% | -3045.5% | +11.8% | +40.7% |
| Profit margin | -41.9% | -58.3% | -156.5% | -2.2% | -59.1% | -47.6% | -25.3% |